drugset / Trial / NCT01639014

Effect of F2695 on Functional Recovery After Ischemic Stroke

NCT01639014

Phase 3 Completed 532 enrolled Pierre Fabre Laboratories
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to assess the efficacy of a new serotonin-norepinephrine reuptake inhibitor (SNRI) nin functional recovery after ischemic stroke.

Timeline

Start
2012-07
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Levomilnacipran Small molecule 75 mg

Indications